Lifeline Scientific, Inc French national tender win (3128B)
March 03 2014 - 1:02AM
UK Regulatory
TIDMLSI
RNS Number : 3128B
Lifeline Scientific, Inc
03 March 2014
3 March 2014
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
French national tender win
Lifeline Scientific (AIM: LSI, LSIC), the transplantation
technology company, announces that its wholly owned subsidiary,
Organ Recovery Systems, has been awarded a major national tender to
supply LifePort(R) Kidney Transporters ('LifePort') and related
products to 23 renal transplant programmes in France. This is the
first national tender award in the EU for the Company.
The competitive tender was organized by UniHA, France's largest
Health Cooperative Group, in co-operation with the French national
authority for transplantation, L'Agence de la Biomédecine. The
tender for the supply of machine preservation products followed the
publication of clinical guidelines in France for machine perfusion
of all deceased donor expanded criteria ('ECD') kidneys. ECDs are
medically viable donors who present with one or more comorbidities
such as age, hypertension, or diabetes mellitus.
In France, approximately half of donated kidneys come from ECDs.
LifePort machine perfusion of ECD kidneys has been shown to improve
patient outcomes, by reducing the risk of delayed graft function
('DGF') and increasing graft survival.(1,2) DGF is known to
adversely impact near and long term graft performance and survival
rates.
The tender award is for a three year term with a one year
renewal option. It calls for Organ Recovery Systems to provide
LifePort Kidney Transporters, plus, installation, commissioning and
maintenance of machinery, consumables and accessories for perfusion
and transport of kidneys.
LifePorts are presently employed by surgeons in over 160
transplant programmes across 27 countries, with over 47,000
clinical procedures to date. France is the largest market in Europe
for kidney transplants with 2,687 deceased donor kidney transplant
procedures reported in 2012.
David Kravitz, CEO of Lifeline Scientific, commented:
"We are delighted to have won this competitive tender in
Europe's largest renal transplant market. We are grateful for the
opportunity to provide technology that will help the French
transplant surgical community bring life changing benefits to
transplant patients."
References:
1. Moers C et al. N Engl J Med 2009; 360(1): 7-19.
2. Moers C et al. N Engl J Med 2012; 366(8): 770-771.
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500
Freddy Crossley/Fred Walsh (Corporate
Finance)
Adam Pollock (Corporate Broking)
Walbrook Tel: +44 (0)20 7933 8780 or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product is the market-leading and
clinically validated LifePort Kidney Transporter. Devices for
preservation of the liver, pancreas, heart and lung are in late
stage pre-clinical development. For more information please visit
www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to provide improved kidney preservation, evaluation and
transport prior to transplantation. Today, it is widely recognised
as the world's leading machine preservation device for kidneys.
Employed by surgeons in over 160 leading transplant programmes in
27 countries worldwide, LifePorts have successfully preserved over
47,000 kidneys indicated for clinical transplant. For more
information please visit www.organ-recovery.com
Lifeline Scientific, Inc. Shares
As a US Company listed on the London Stock Exchange's AIM
exchange, Lifeline Scientific, Inc. (AIM: LSI, LSIC) trades under
two lines of stock. While affiliates of the Company are required to
hold restricted (RegS) shares, all others may hold restricted or
unrestricted shares. Unrestricted shares may be electronically
traded through the CREST system. Both lines of stock have identical
rights, preferences and privileges. Non-affiliates may transfer
restricted shares to the unrestricted line after purchase through
the Company's registrar. Total shares outstanding for the Company
at this time are 19,446,959.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLLLBZXFXBBK
Lifeline Sci. S (LSE:LSI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Lifeline Sci. S (LSE:LSI)
Historical Stock Chart
From Jan 2024 to Jan 2025
